The current Exhibition Floorplan is here for you to view the overall Exhibition layout.
However, please use the interactive floorplan (here) to view the stands available (and booked) as this is updated as bookings are confirmed.
The Exhibition Manual is here for you to download.
Exhibitors at ECE2017
We are delighted to welcome the following exhibiting companies to ECE2017:
Stand 1: Phoenix Europe GmbH
||Phoenix specialises in peptite assays for obesity, cardiovascular, diabetes and endocrine related hormones. Other products include endocrinology related peotides and antibodies. Our newer products are non-radioactive, hightly sensitive fluroescent and chemiluminescent EIA assays as well as Magnetic Bead RIA assays which require as little as 5ul of sample. Irisin, Betatrophin and Insulin Like Peptide related productes are availble now. Phoenix also offers the service of hormone level dtermination; where the tedious extraction and assay procedures are performed for you. Our long term experience in custom peptide synthesis and custom peptide labelling is apprecaited by our customers as well. With over 40 obesity-realted peptides in publications today, Phoenix Pharmaceuticals is always the leader in obesity related peptide discoveries.|
Stand 2: The Endocrine Society
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.
The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. We have more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. We are passionate about advancing hormone research, excellence in the clinical practice of endocrinology, broadening understanding of the critical role hormones play in human health, and advocating on behalf of the field of endocrinology in the global policy community. Visit endocrine.org
To learn more and follow us on Twitter at @TheEndoSociety and @EndoMedia.
Stand 3: EndoBridge 2017
On behalf of the Endocrine Society, European Society of Endocrinology and the Society of Endocrinology and Metabolism of Turkey, we are delighted to invite you to attend the fifth EndoBridge® meeting that will take place in Antalya, Turkey, October 19-22, 2017.
EndoBridge 2017 will provide a comprehensive update of recent advances in the full spectrum of endocrinology including diabetes and lipid disorders. The program involves state-of-the-art lectures delivered by world-renowned faculty as well as interactive case discussion sessions.
The official language of the meeting is English and simultaneous translation in Russian, Arabic and Turkish will be provided.
We expect EndoBridge 2017 to bring together leading experts of endocrinology and a diverse and active international scientific community of clinicians and fellows to present and discuss clinical endocrinology topics.
Antalya, the heart of the Turkish Riviera, is an exceptional venue blending history and culture with a majestic coastline of shiny beaches.
Please visit the EndoBridge® Booth to learn more about this event.
Stand 4:AACE Amercial Association of Clinical Endocrinologists
AACE, established in 1991, is a professional medical community of clinical endocrinologists and physicians that treat endocrine disorders. AACE is committed to enhancing its members’ ability to provide the highest quality of care. As the country’s largest professional organization of clinical endocrinologists, AACE has more than 7,500 members in 97 countries, who are devoted to providing care for patients with endocrine disorders. Please visit the AACE Membership Booth for applications, our clinical guidelines, and all the latest information and resources for physicians and your patients. www.aace.com.
Stand 5: AdrenalNET
AdrenalNET is working to make improvements to the care provided to people with adrenal disorders in the following ways:
AdrenalNET offers patients with adrenal gland disorders and their carers:
AdrenalNET offers healthcare practitioners:
Stand 6: Karger
Karger Publishers is a leading international publisher of medical and scientific journals and books. Currently, production comprises close to 100 scientific journals and about 50 book titles per year, both research and clinical, the majority of which are in English. Karger publications are indexed in all important bibliographical services, such as PubMed. Connecting people who want to share their knowledge with those who want to learn, the publisher's main concern is to provide high-quality content.
Publications in endocrinology include the book series 'Endocrine Development' (Series Editor: P.E. Mullis), 'Frontiers of Hormone Research' (Series Editor: E. Ghigo) and 'Frontiers in Diabetes' (Series Editors: M. Porta, F.M. Matschinsky). Visit our booth and browse our wide selection of books in adult and pediatric endocrinology. New publications include 'Endocrine Immunology', 'Diabetes Associated with Single Gene Defects and Chromosomal Abnormalities' and 'Practical Algorithms in Pediatric Endocrinology'.
Journals of particular interest to participants are the 'European Thyroid Journal' (Editor-in-Chief: W.M. Wiersinga), 'Hormone Research in Paediatrics' (Editor-in-Chief: S. Cianfarani), 'Neuroendocrinology' (Editor-in-Chief: R.P. Millar) and 'Obesity Facts' (Editor-in-Chief: H. Hauner) – free sample copies are available.
Publications are accessible online at www.karger.com/endocrinology with free abstracts, full-text search of articles and many other services.
Stand 7 & 8: Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Aegerion is currently focused on developing treatments for generalized lipodystrophy and a subset of patients with partial lipodystrophy.
Lipodystrophy syndromes are ultra-rare disorders characterised by loss of adipose tissue. In patients with lipodystrophy syndromes, levels of leptin are often very low. Leptin is a naturally occurring hormone produced in adipose tissue and is an important regulator of energy homoeostasis, fat and glucose metabolism, reproductive capacity, and other diverse physiological functions. Lipodystrophy is often associated with severe metabolic abnormalities, including significantly elevated triglycerides, insulin resistance, and/or diabetes, which can result in life-threatening co-morbidities such as acute pancreatitis, steatohepatitis, and/or accelerated atherosclerosis and early mortality. In addition, deposition of fat may occur in ectopic locations such as liver, heart, and muscle, leading to extreme insulin resistance and often to diabetes that is difficult to control.
Leptin is a naturally occurring hormone and an important regulator of energy homeostasis, fat and glucose metabolism. Metreleptin is an analogue of leptin made through recombinant DNA technology and has been studied as a replacement therapy, in addition to diet, in patients with generalized or partial lipodystrophy.
In December 2016, Aegerion submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in a subset of patients with partial lipodystrophy (PL).
Aegerion Pharmaceuticals is a subsidiary of Novelion Therapeutics. Novelion is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases.
Stand 9: Pfizer Medical (Rare Diseases)
Stand 11: Thermo Fisher Scientific
B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, investigates, develops and manufactures novel diagnostic testing procedures to improve early diagnosis and treatment of life threatening diseases. With high-quality immunodiagnostic tests for prenatal screening, cardiovascular, pulmonary, and cancer disorders as well as particularly for sepsis, the company contributes to the creation of a healthier future – to the greatest advantage for medical professionals and patients.
B·R·A·H·M·S GmbH is leading in specific market places and therapeutic areas. The aim of its basic research is to identify new biomarkers, with support by international co-operations and reputable research institution.
Thermo Fisher Scientific, B·R·A·H·M·S GmbH, Neuendorfstr. 25, 16761 Hennigsdorf, Germany.
tel. +49 3302 883-0
fax +49 3302 883-100
Stand 12: Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.
Stand 14: Ipsen
Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases.
Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from neuro-endocrine tumors, prostate cancer, bladder cancer, pancreatic cancer and renal cancer. Ipsen also has a significant presence in primary care.
Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditures neared €193 million.
The Group has more than 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and are eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trades on the over-the-counter market in the United States under the symbol IPSEY.
For more information on Ipsen, visit www.ipsen.com.
Stand 16: HRA Pharma
HRA Pharma is a leading pharmaceutical company with a unique leadership position within niche areas in women’s health and endocrinology/rare diseases. The company is committed to understand evolving health needs, bringing adequate health solutions and developing actions for equal access to its products amongst patients and physicians throughout the globe.
In the field of endocrinology/rare diseases our ambition is to make meaningful health solutions broadly accessible to rare disease patients. Currently, HRA Pharma has three treatment options in its portfolio that address Cushing’s Syndrome (CS) and Adrenal Cortical Carcinoma (ACC).
•Metopirone®/Metopiron®/Cormeto®/Metycor® (metyrapone, 250 mg, soft capsule), a drug marketed available in 14 European countries and indicated, in 17 European countries, for in the management of patients with endogenous Cushing's syndrome and, as a diagnostic test for ACTH insufficiency and as a diagnostic test in the differential diagnosis of ACTH-dependent Cushing's syndrome.
•Ketoconazole HRA® (ketoconazole, 200 mg, tablet), newly registered as an orphan drug, specifically indicated for the treatment of endogenous Cushing’s Syndrome Syndrome in adults and adolescents above the age of 12 years.
•Lysodren® (mitotane, 500 mg, tablet), an orphan drug for the symptomatic treatment of advanced Adrenal Cortical Carcinoma (the effect of Lysodren® on non functionalnon-functional ACC is not established); and its Lysosafe® Service, a free-of-charge mitotane plasma level monitoring service which helps physicians optimise efficacy and safety of Lysodren® treatment.
For more information, visit our corporate website www.hra-pharma.com
For any medical requests, please contact us at firstname.lastname@example.org
Stand 17: Shire
Stand 18: Novartis
Novartis Oncology is a global leader in improving outcomes for people living with cancer. We seek to transform cancer care through distinctive scientific and clinical strategies focused on developing targeted, immuno-oncology and combination therapies to create more effective options for patients. The company offers a wide range of innovative therapies and our oncology pipeline is one of the strongest and most productive in the industry. Our unique global capabilities support the strategy with research and broad operational facilities worldwide.
The robust R&D program has enabled Novartis Oncology to offer a wide range of mature and innovative patented products to help physicians meet patient needs, including Afinitor® (everolimus), Arzerra® (ofatumumab), Desferal® (deferoxamine), Exjade® (deferasirox), Farydak® (panobinostat), Femara® (letrozole), Glivec® (imatinib mesylate), Jakavi® (ruxolitinib), Mekinist™ (trametinib dimethyl sulfoxide), Odomzo® (sonidegib), Revolade® (eltrombopag olamine), Sandostatin® LAR® (octreotide), Signifor® (pasireotide), Tafinlar® (dabrafenib mesylate), Tasigna® (nilotinib), Tyverb® (lapatinib ditosylate), Votrient® (pazopanib hydrochloride), Zometa® (zoledronic acid) and Zykadia™(ceritinib). Novartis also has one of the broadest and most comprehensive oncology pipelines in the industry with more than 20 compounds in various stages of clinical trials.
We share a common goal with the global oncology community – to improve and extend the lives of patients. Through open partnerships with the community we gain and build knowledge, driving clinical development based on scientific and patient insights. Partnering with healthcare professionals enables us to conduct high-quality clinical trials with competitive timelines and aids in the discovery of new uses of our medicines. Engagement with advocacy groups helps us better understand patient needs and barriers to treatment success. Collaboration with health authorities helps us to speed delivery of new treatments for patients.
For more information about how we are transforming the treatment of cancer and other diseases, please visit www.novartisoncology.com.
Stand 19: European Society of Endocrinology (ESE)
At the European Society of Endocrinology, we’re working together to develop and share the best knowledge in endocrine science and medicine.
We’re shaping the future of endocrinology to improve science, knowledge and health across Europe and beyond. Improving our science will make patient care better. By uniting, supporting and representing our community, we can help drive better medical outcomes throughout endocrinology.
Sharing knowledge, promoting best practice, influencing policy, and enabling collaboration are crucial to how we go about our work. Together, these approaches mean we sit at the center of Europe’s endocrine community.
Come and visit the ESE Team on stand 19 to find out more about membership and all our exciting activities.
ESE: Advancing European endocrinology.
Stand 20: AmCad Bio
AmCad BioMed Corporation is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. The company has successfully developed and commercialized a series of the pioneering, first-in-the-world medical devices.
AmCad's strong pipeline includes AmCAD-UT (FDA, CE Mark and TFDA, for thyroid nodules analysis), AmCAD-CA (for cytopathology analysis), iSONO accessory (revolutionizing ultrasound imaging), AmCAD-US (CE Mark, for backscattered signals analysis),AmCAD-UV (CE Mark, for classifying pulsatile), and AmCAD-UO (for obstructive sleep apnea detection). The state-of-the-art pipeline aims for early detection and diagnosis of various types of cancers, such as thyroid and breast cancers, and diseases, including organ tissue fibrosis and obstructive sleep apnea, etc.
AmCAD-UT is the ultimate diagnostic solution for thyroid ultrasound images, and by far the world’s first and only commercially available ultrasound CAD specifically designed for thyroid nodules with FDA and CE Mark marketing clearance. Our patent-protected system to quantify and visualize suspicious features for malignancy has been proven to improve diagnosis accuracy and consistency. With the non-invasive, pain-free procedure and detailed reporting system, AmCAD-UT not only avoids unnecessary Fine-Needle Aspiration and surgeries but also makes follow-up of thyroid nodules a lot easier, for both patients and physicians.With the proprietary image calibration technology, AmCAD-UT is compatible with all available ultrasound systems and PACS.AmCAD-CA is the only commercially available software device specifically designed for cytopathology analysis. AmCAD-CA features visualization and quantification of clinical characteristics, such as nucleus size, circularity, polarity, elongation, nuclear-cytoplasm ratio, inclusion bodies, etc. For diagnosis of thyroid nodules, AmCAD-CA assists medical professionals in analyzing the quantified morphological cytology features to improve their diagnostic accuracy and consistency
Stand 21: StrongBridge Biopharma
Strongbridge Biopharma is a global commercial biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine disease franchise includes RECORLEV (levoketoconazole), or COR-003, currently being studied in a multinational Phase 3 program as a treatment for endogenous Cushing’s syndrome. This program includes the currently enrolling SONICS study and the forthcoming LOGICS study. Veldoreotide, or COR-005, is in clinical development for acromegaly. The safety and efficacy of levoketoconazole and veldoreotide have not been established. The focus of Strongbridge’s rare neuromuscular franchise is primary periodic paralysis, for which it has US rights to an FDA-approved commercial product.
Rare Focus. Rare Commitment. Rare Passion.
Please visit www.strongbridgebio.com to learn more.
The International Congress of Endocrinology (ICE) will take place in Cape Town, South Africa, from 1 to 4 December 2018. The Programme Organising Committee is putting together a stimulating programme including cutting-edge academic endocrinology for basic scientists and clinicians, as well as practical clinical sessions empowering doctors with the knowledge to optimise care for their patients with endocrine disorders.
Stand 23: International Society of Endocrinology
Since its foundation in 1960, the International Society of Endocrinology (ISE) has pursued the worldwide advancement of education, science and patient care in Endocrinology.
Stand 24: Wisepress Medical Bookshop
Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.
15 Lyon Roadm, Merton, London SW19 2RL
Phone: +44 20 8715 1812